Description
Calvenza™ EHV is Equine Rhinopneumonitis Vaccine Killed Virus Vaccine.

Features
•Unique EHV-1 equine respiratory origin isolate.
•Stimulates antibody to EHV-1 EVH-4.
•Proven efficacious against EHV-1 EHV-4 in challenge studies.
•Novel adjuvant.
•Safe all killed vaccine.
•Includes innovative pliable nasal applicator.

Benefits
•Aids in reduction of respiratory disease caused by EHV-1 EHV-4.
•Flexible dose administration.
•No reversion to virulence concern.
•Minimal vaccine site reactions.
•Three dose regimen conforms to AAEP recommendations.

Advantages
Calvenza™ EHV is proven safe. Calvenza™ EHV is proven effective by challenge.

Dosage Administration
Using aseptic technique inoculate horses IM with a 2 mL dose. Administer a second 2 mL dose IM in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks either IM or IN. Revaccinate annually and prior to anticipated exposure either IM or IN.

Precautions
Store at a temperature between 35° - 45° F (2° - 7° C). Protect from freezing. Shake well before using. Do not vaccinate within 21 days of slaughter.Antidote: Epinephrine.

Uses
For the vaccination of healthy susceptible horses 6 months of age or older including pregnant mares as an aid in the reduction of respiratory disease due to equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4).

Warning
This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal healthy immunocompetent animals. This level of performance may be affected by conditions such as stress weather nutrition disease parasitism other treatments individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.

Highlights
•Unique EHV-1 antigen novel adjuvant.
•Proven efficacious against EHV-1 EHV-4 by challenge studies.
•Flexible routes of administration.
•Proven safe with minimal vaccine site reaction.
•Safe for use in pregnant mares.